Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials

BACKGROUND: Galcanezumab is a novel monoclonal antibody that target to calcitonin gene-related peptide (CGRP). It has been tested for the preventive treatment of migraine and episodic cluster headache by multiple randomized clinical trials (RCTs) and have been found to reduce headache frequency. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yanbo, Wang, Zilan, Gao, Bixi, Xuan, He, Zhu, Yun, Chen, Zhouqing, Wang, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014619/
https://www.ncbi.nlm.nih.gov/pubmed/32046655
http://dx.doi.org/10.1186/s10194-020-1085-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014619/
https://www.ncbi.nlm.nih.gov/pubmed/32046655
http://dx.doi.org/10.1186/s10194-020-1085-x

Ejemplares similares